The Effect of Oxytocin on Gastric Emptying

This study has been completed.
Information provided by (Responsible Party):
Bodil Ohlsson, Skane University Hospital Identifier:
First received: June 23, 2010
Last updated: April 6, 2015
Last verified: April 2015
The investigators have seen that oxytocin lowers satiety in healthy subjects. Patients with dyspepsia suffers from decreased accommodation and increased satiety postprandially. The investigators now want to examine whether oxytocin may diminish symptoms in these patients.

Condition Intervention
Lack of Satiety
Drug: oxytocin

Study Type: Interventional
Study Design: Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Caregiver)
Primary Purpose: Treatment
Official Title: The Effect of Oxytocin on Satiety in Patients With Dyspepsia

Resource links provided by NLM:

Further study details as provided by Skane University Hospital:

Primary Outcome Measures:
  • Satiety [ Time Frame: 2 h ] [ Designated as safety issue: No ]
    The investigator want to examine whether oxytocin leads to lower satiety scores after intake of the same volume of nutrient

Other Outcome Measures:
  • To see if oxytocin lowers satiety [ Time Frame: 2h ] [ Designated as safety issue: No ]
    To perform a drinking satiety test twice. Once with oxytocin and once with saline. Then examine whether oxytocin decreases satiety compared to saline

Enrollment: 14
Study Start Date: May 2010
Study Completion Date: April 2015
Primary Completion Date: April 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: oxytocin, satiety
Oxytocin is given as infusion to examine if this decreases satiety compared to saline during a drinking test
Drug: oxytocin
40mU/min as infusion of oxytocin
Other Name: syntocinon

Detailed Description:
Patients will come twice for a slow satiety drinking test. Once they will get saline infusion and once oxytocin 40 mU/min. At the same time they register satiety on a VAS scale.

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Dyspepsia

Exclusion Criteria:

  • Age > 65 years
  • Cardiac disease
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01152047

Skåne University Hospital
Malmö, Sweden, 205 02
Sponsors and Collaborators
Skane University Hospital
Principal Investigator: Bodil Ohlsson, professor Divsion of Internal Medicine
  More Information

Responsible Party: Bodil Ohlsson, Department of Clinical Sciences, Division of Internal Medicine, Skane University Hospital Identifier: NCT01152047     History of Changes
Other Study ID Numbers: 2009/502  2009/502 
Study First Received: June 23, 2010
Last Updated: April 6, 2015
Health Authority: Sweden: Regional Ethical Review Board

Keywords provided by Skane University Hospital:

Additional relevant MeSH terms:
Signs and Symptoms
Signs and Symptoms, Digestive
Physiological Effects of Drugs
Reproductive Control Agents processed this record on May 24, 2016